NeuroSense Therapeutics

NRSN

Market cap $26.5M

Overview Fund Trends Analyst Outlook Journalist POV

1.06 USD

--0.04

3.64%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

1.05

--0.01

0.94%

1 day

-3.64%

5 days

-11.67%

1 month

-15.2%

3 months

-42.7%

6 months

9.28%

Year to date

-7.83%

1 year

-20.9%

5 years

-73.76%

10 years

-73.76%

About: NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Employees: 15

Healthcare Biotechnology